These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21325472)

  • 1. Lessons from MATRICS.
    Marder SR
    Schizophr Bull; 2011 Mar; 37(2):233-4. PubMed ID: 21325472
    [No Abstract]   [Full Text] [Related]  

  • 2. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.
    Nuechterlein KH; Green MF; Kern RS; Baade LE; Barch DM; Cohen JD; Essock S; Fenton WS; Frese FJ; Gold JM; Goldberg T; Heaton RK; Keefe RS; Kraemer H; Mesholam-Gately R; Seidman LJ; Stover E; Weinberger DR; Young AS; Zalcman S; Marder SR
    Am J Psychiatry; 2008 Feb; 165(2):203-13. PubMed ID: 18172019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.
    Green MF; Nuechterlein KH; Kern RS; Baade LE; Fenton WS; Gold JM; Keefe RS; Mesholam-Gately R; Seidman LJ; Stover E; Marder SR
    Am J Psychiatry; 2008 Feb; 165(2):221-8. PubMed ID: 18172017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The treatment of negative symptoms: pharmacological and methodological issues.
    Carpenter WT
    Br J Psychiatry Suppl; 1996 May; (29):17-22. PubMed ID: 8733819
    [No Abstract]   [Full Text] [Related]  

  • 5. Clozapine, cognition, and schizophrenia.
    Launer M
    Br J Psychiatry; 1993 Apr; 162():567-8. PubMed ID: 8481757
    [No Abstract]   [Full Text] [Related]  

  • 6. [Methodological approaches to the assessment of cognitive symptoms during psychopharmacotherapy].
    Tsygankov BD; Khananova AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(10):66-71. PubMed ID: 21510452
    [No Abstract]   [Full Text] [Related]  

  • 7. Medicine. What are the right targets for psychopharmacology?
    Hyman SE; Fenton WS
    Science; 2003 Jan; 299(5605):350-1. PubMed ID: 12532001
    [No Abstract]   [Full Text] [Related]  

  • 8. [New drug therapies].
    Olié JP; Baylé FJ
    Encephale; 1996 Oct; 22 Spec No 3():63-71; discussion 76. PubMed ID: 8954280
    [No Abstract]   [Full Text] [Related]  

  • 9. Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
    Keefe RS; Meltzer HA; Dgetluck N; Gawryl M; Koenig G; Moebius HJ; Lombardo I; Hilt DC
    Neuropsychopharmacology; 2015 Dec; 40(13):3053-60. PubMed ID: 26089183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase Targets for Cognitive Dysfunction and Schizophrenia--a New York Academy of Sciences Meeting.
    Zhang HT
    IDrugs; 2010 Mar; 13(3):166-8. PubMed ID: 20191432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of atomoxetine on cognitive function and cigarette smoking in schizophrenia.
    Sacco KA; Creeden C; Reutenauer EL; Vessicchio JC; Weinberger AH; George TP
    Schizophr Res; 2009 Feb; 107(2-3):332-3. PubMed ID: 18995989
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical symptoms, mainly negative symptoms, mediate the influence of neurocognition and social cognition on functional outcome of schizophrenia.
    Lin CH; Huang CL; Chang YC; Chen PW; Lin CY; Tsai GE; Lane HY
    Schizophr Res; 2013 May; 146(1-3):231-7. PubMed ID: 23478155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.
    Keefe RS; Fox KH; Harvey PD; Cucchiaro J; Siu C; Loebel A
    Schizophr Res; 2011 Feb; 125(2-3):161-8. PubMed ID: 21075600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychotropic effects of ritanserin, a selective S2 antagonist: an open study.
    Strauss WH; Klieser E
    Eur Neuropsychopharmacol; 1991 May; 1(2):101-5. PubMed ID: 1821698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Important steps in the development of cognitive-enhancing drugs in schizophrenia.
    Buchanan RW
    Am J Psychiatry; 2006 Nov; 163(11):1867-9. PubMed ID: 17074932
    [No Abstract]   [Full Text] [Related]  

  • 16. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.
    Kern RS; Nuechterlein KH; Green MF; Baade LE; Fenton WS; Gold JM; Keefe RS; Mesholam-Gately R; Mintz J; Seidman LJ; Stover E; Marder SR
    Am J Psychiatry; 2008 Feb; 165(2):214-20. PubMed ID: 18172018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical antipsychotic drugs improve cognition in schizophrenia.
    Meltzer HY; Sumiyoshi T
    Biol Psychiatry; 2003 Feb; 53(3):265-7; author reply 267-8. PubMed ID: 12559661
    [No Abstract]   [Full Text] [Related]  

  • 18. Psychopharmacologic treatment of negative schizophrenic symptoms.
    Opler LA; Albert D; Ramirez PM
    Compr Psychiatry; 1994; 35(1):16-28. PubMed ID: 7908618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thinking patterns and patterning drugs.
    Seeman MV
    Can J Psychiatry; 1997 Apr; 42(3):247-8. PubMed ID: 9114939
    [No Abstract]   [Full Text] [Related]  

  • 20. Cognitive neuroscience and schizophrenia: translational research in need of a translator.
    Cohen JD; Insel TR
    Biol Psychiatry; 2008 Jul; 64(1):2-3. PubMed ID: 18549873
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.